Bridge Therapeutics

Executive Summary

Bridge Therapeutics is a private, development-stage biopharmaceutical company headquartered in San Diego, CA, focused on addressing the opioid crisis through safer and more effective treatments for opioid use disorder (OUD) and chronic pain. The company's lead candidates are BT-219, a novel formulation of buprenorphine-naloxone designed to improve patient compliance and reduce abuse potential, and BT-205, a patented drug combination for chronic pain in opioid-experienced patients, aiming to provide effective analgesia with lower addiction risk. With the U.S. facing an urgent need for non-addictive pain management and better OUD therapies, Bridge Therapeutics' pipeline targets large, underserved markets. The company is currently advancing both programs through preclinical and early clinical development, supported by a management team with deep expertise in CNS disorders. While still in early stages, Bridge's differentiated approach and focus on safety could make it an attractive partner or acquisition target for larger pharmaceutical companies seeking to expand in pain and addiction therapeutics.

Upcoming Catalysts (preview)

• Q3 2026Topline Phase 1 Safety and PK Data for BT-219 in OUD70% success
• Q2 2026IND Filing for BT-205 in Chronic Pain80% success
• H2 2026Series A/B Financing Round to Support Phase 2 Readiness60% success